{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:03:50Z","timestamp":1787943830491,"version":"build-2784847793"},"reference-count":14,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>Introduction: Azacitidine + venetoclax is a new standard of care for acute myeloid leukemia not eligible for intensive chemotherapy. This combination is associated with hematological toxicities and some drug interactions. Real-world studies have shown a decrease in results and outcomes when compared to the VIALE-A study. Methods: We report here our single-center experience using AZA + VEN, rigorously following management guidelines from the VIALE-A study, applied to a real-life population. Results: Forty-two AML patients were analyzed. The complete remission (CR)\/CR with incomplete recovery (CRi)\/MLFS rate was 73.8% after 1 cycle with 51% CR\/CRi and 80.9% after 2 cycles. Median overall survival was 18 months (95% CI, 10.3\u201325.7). Our retrospective study showed that rigorous use of AZA + VEN in a real-world setting was associated with results close to clinical trial observations. Conclusion: We showed the need to rigorously follow AZA+VEN dosage but also toxicity guidelines and practice recommendations edited in the clinical trial even in the real world.<\/jats:p>","DOI":"10.1159\/000548334","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:00:43Z","timestamp":1759161643000},"page":"1-5","source":"Crossref","is-referenced-by-count":2,"title":["Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial"],"prefix":"10.1159","author":[{"given":"Bochra","family":"Sedaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Iat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Benachour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Risso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Abichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Ferrero-Vacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neila","family":"De Pooter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Mouanes-Abelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berengere","family":"Dadone-Montaudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650473"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011181"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163617"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key109"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165464"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2265206"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000243"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082025"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx427"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000548334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:01:07Z","timestamp":1762880467000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000548334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":14,"URL":"https:\/\/doi.org\/10.1159\/000548334","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}